Elizabeth Wulff-Burchfield, MD, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.
Elizabeth Wulff-Burchfield, MD, assistant professor, Divisions of Medical Oncology and Palliative Medicine and medical director of Palliative and Geriatric Oncology Services, The University of Kansas Health System, advises physicians on how to make appropriate treatment decisions for patients with unresectable kidney cancer.
Treatment decisions should primarily depend on several patient characteristics, such as their functional status, goals for treatment, and tolerance for medical burden, Wulff-Burchfield says. Should the patient’s goal be to pursue more aggressive care and systemic therapy in order to both achieve good responses and improve symptom burden, she says she would prioritize treatment based on overall responses rates.
For patients who are more medically frail, or have comorbidities putting them at a higher risk for a rapid decline in function status or overall well-being, it is reasonable to consider a single-agent tyrosine inhibitor, according to Wulff-Burchfield. If a patient can tolerate more aggressive care, it would be appropriate to use a tyrosine kinase inhibitor in combination with an immune checkpoint inhibitor.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More